CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Stock Chart & Stats
$67.70
-$0.55(-1.77%)
At close: 4:00 PM EST
$67.70
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$19.47 - $71.90
Previous Close$30.46
Volume740.02K
Average Volume (3M)1.47M
Market Cap
$5.72B
Enterprise Value$5.69B
Total Cash (Recent Filing)$742.15M
Total Debt (Recent Filing)$7.02M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
May 07, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding84,435,200
10 Day Avg. Volume1,152,346
30 Day Avg. Volume1,466,796
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.41K
Enterprise Value/Gross Profit-9.38K
Enterprise Value/Ebitda-34.02
Forecast
1Y Price Target
$88.33Price Target Upside30.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.35
Revenue Forecast (FY)$21.54M
Bulls Say, Bears Say
Bulls Say
Durable Efficacy And Immune MemoryAnalyst recommends the stock because the therapy's immune-stimulating mechanism is expected to produce durable recurrence control and immune memory that could reduce repeat surgeries for patients.
Pivotal Trial Progress And Regulatory PathwayRapid enrollment in the pivotal randomized registrational trial accelerates availability of mature recurrence-free survival data and strengthens the potential for a favorable regulatory review and filing.
Safety Profile And Broader ApplicabilityClean safety findings with few severe events and consistent activity across multiple non-muscle invasive bladder cancer populations support potential expansion into broader indications and a sizable market opportunity.
Bears Say
Clinical Durability RiskAnalyst cautions that failure to show sustained reduction in recurrence would limit guideline adoption and undermine the investment case for the therapy.
Liquidity And Investor SentimentHigh cash burn and notable short interest create financing needs and investor skepticism that could pressure the company's stock and constrain long-term development plans.
Trial Design And Comparator UncertaintyAbsence of a chemotherapy control and lack of a head-to-head comparison with common immunotherapies increases uncertainty about real-world benefit and could make clinician uptake more difficult.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $19.47 and its highest was $71.90 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $5.72B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Feb 27, 2026. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.6 by $0.05.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.56.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 84,435,200 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.6. Following the earnings report the stock price went up 4.794%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.33 (30.47% Upside)
$88.33 (30.47% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 44.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
284.00%
12-Months-Change
Fundamentals
Return on Equity
-22.87%
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$88.33
▲(30.47% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
10.37% Insiders
25.00% Mutual Funds
38.07% Other Institutional Investors
12.64% Public Companies and
Individual Investors